These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1225 related articles for article (PubMed ID: 7774641)

  • 1. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
    Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
    J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
    Frisan T; Zhang QJ; Levitskaya J; Coram M; Kurilla MG; Masucci MG
    Int J Cancer; 1996 Oct; 68(2):251-8. PubMed ID: 8900437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
    Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
    Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells.
    Khanna R; Cooper L; Kienzle N; Moss DJ; Burrows SR; Khanna KK
    J Immunol; 1997 Dec; 159(12):5782-5. PubMed ID: 9550373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
    Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
    Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
    Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
    J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RelB nuclear translocation mediated by C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells.
    Pai S; O'Sullivan BJ; Cooper L; Thomas R; Khanna R
    J Virol; 2002 Feb; 76(4):1914-21. PubMed ID: 11799186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
    Khanna R; Burrows SR; Suhrbier A; Jacob CA; Griffin H; Misko IS; Sculley TB; Rowe M; Rickinson AB; Moss DJ
    J Immunol; 1993 Jun; 150(11):5154-62. PubMed ID: 7684421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines.
    Frisan T; Levitsky V; Polack A; Masucci MG
    J Immunol; 1998 Apr; 160(7):3281-9. PubMed ID: 9531285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2.
    Lee SP; Thomas WA; Blake NW; Rickinson AB
    Eur J Immunol; 1996 Aug; 26(8):1875-83. PubMed ID: 8765034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma.
    Niedobitek G; Agathanggelou A; Rowe M; Jones EL; Jones DB; Turyaguma P; Oryema J; Wright DH; Young LS
    Blood; 1995 Jul; 86(2):659-65. PubMed ID: 7605996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.
    Murray RJ; Young LS; Calender A; Gregory CD; Rowe M; Lenoir GM; Rickinson AB
    J Virol; 1988 Mar; 62(3):894-901. PubMed ID: 2828684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40 cross-linking enhances the immunogenicity of Burkitt's-lymphoma cell lines.
    Frisan T; Donati D; Cervenak L; Wilson J; Masucci MG; Bejarano MT
    Int J Cancer; 1999 Dec; 83(6):772-9. PubMed ID: 10597194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.
    Murray PG; Constandinou CM; Crocker J; Young LS; Ambinder RF
    Blood; 1998 Oct; 92(7):2477-83. PubMed ID: 9746788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines.
    Cuomo L; Trivedi P; de Campos-Lima PO; Zhang QJ; Ragnar E; Klein G; Masucci MG
    Mol Immunol; 1993 Apr; 30(5):441-50. PubMed ID: 7681932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
    Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
    J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.